A Single and Multiple Ascending Dose, Placebo-Controlled, Double-Blind, Phase 1 Study of KY1005 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 30 Jul 2018
At a glance
- Drugs KY-1005 (Primary)
- Indications Autoimmune disorders; Graft-versus-host disease
- Focus Adverse reactions
- Sponsors Kymab
- 30 Jul 2018 According to a Kymab media release, the first subject first visit took place in June 2017 with last subject visit in March 2018.
- 30 Jul 2018 According to a Kymab media release, company has announced positive results of this study.
- 16 May 2018 Status changed from recruiting to completed.